PD-L1 Blockade 4. PD-1/PD-L1药物研究进展目前,已在全球范围内上市并应用的PD-1/PD-L1抗体类药物总共有六个,对应的适应症表一所示,其中Cemiplimab作为全球第3款PD-1抑制剂Cemiplimab(商品名Libtayo)。主要用于治疗转移性皮肤鳞状细胞癌(CSCC)或局部晚期不可切除的CSCC患者。这也是全球唯一一个治疗皮肤鳞状细胞
所以,免疫检查点阻断(Immune Checkpoint Blockade)疗法是激活抗肿瘤免疫的有效方法。用抗体阻断免疫检查点,增强或抑制免疫细胞与“敌人”或“队友”间的交流信号,调节检查力度,即可增强原有的抗肿瘤免疫活性,为患者提供针对肿瘤的持久免疫应答。 在医学不断发展的今天,我们不仅知道免疫检查点在“检查什么”,还在一定程度...
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Tumeh, et al., Science (2014) Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Spranger et Nature. (2015) Roche’s PD L1 inhibitor Tecentriq: a new contender in non small cell lung cancer, Clarivate...
[7] Fournel L et al. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. Cancer Lett. 2019;464:5-14. [8] Herbst RS et al. Predictive correlates of response to the ...
[1].Drew M. Pardoll. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer. 2012 Mar 22;12(4):252-64. [2].Annika De Sousa Linhares, Claire Battin, Sabrina Jutz, et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/...
最新一份权威数据结果发布在国际顶级期刊《Science》上(Mismatch-repairdeficiencypredictsresponseofsolidtumorstoPD-1blockade)。在这项最新研究中,研究人员共招募了86名MSI阳性的、来自12种癌症的病患,并评估了PD-1抗体对这12种不同晚期肿瘤的治疗效果。
3.Merryman,R.W., et al., Checkpoint blockade inHodgkin and non-Hodgkin lymphoma. Blood advances, 2017. 1(26): p. 2643-2654.
3. Merryman,R.W., et al., Checkpoint blockade inHodgkin and non-Hodgkin lymphoma. Blood advances, 2017. 1(26): p. 2643-2654. 癌度服务项目
3. Merryman,R.W., et al., Checkpoint blockade inHodgkin and non-Hodgkin lymphoma. Blood advances, 2017. 1(26): p. 2643-2654.